Jubilant Pharmova Limited has informed the Exchange about General Updates
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova announced that the USFDA completed a pre-approval inspection (PAI) of its solid dosage formulations facility at Roorkee, India, operated by subsidiary Jubilant Generics Limited, on August 1, 2025. The USFDA issued 4 observations following the audit, and the company stated it will submit an action plan to address them. The Roorkee site contributed less than 1% of Jubilant Pharmova's revenues from the US market in the trailing twelve months (July 2024 to June 2025). The inspection is part of the regulatory process for approving new products manufactured at the facility for the US market.
The financial impact is limited given the site's small revenue contribution (under 1% of US revenues). However, 4 observations need to be addressed promptly to avoid delays in product approvals; the market will watch for the USFDA's response to the company's action plan.